Achieve Life Sciences Inc - Asset Resilience Ratio
Achieve Life Sciences Inc (SP4P) has an Asset Resilience Ratio of 37.03% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Achieve Life Sciences Inc's Asset Resilience Ratio has changed over time. Check SP4P strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Achieve Life Sciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Achieve Life Sciences Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €15.47 Million | 37.03% |
| Total Liquid Assets | €15.47 Million | 37.03% |
Asset Resilience Insights
- Very High Liquidity: Achieve Life Sciences Inc maintains exceptional liquid asset reserves at 37.03% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Achieve Life Sciences Inc Industry Peers by Asset Resilience Ratio
Compare Achieve Life Sciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Achieve Life Sciences Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Achieve Life Sciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.03% | €15.47 Million ≈ $18.09 Million |
€41.79 Million ≈ $48.86 Million |
-18.90pp |
| 2024-12-31 | 55.93% | €21.61 Million ≈ $25.26 Million |
€38.63 Million ≈ $45.17 Million |
-- |
| 2023-12-31 | 0.00% | €0.00 ≈ $0.00 |
€19.37 Million ≈ $22.65 Million |
-- |
| 2019-12-31 | 0.00% | €0.00 ≈ $0.00 |
€21.08 Million ≈ $24.64 Million |
-- |
| 2018-12-31 | 26.67% | €5.09 Million ≈ $5.95 Million |
€19.08 Million ≈ $22.31 Million |
-10.57pp |
| 2016-12-31 | 37.24% | €10.23 Million ≈ $11.96 Million |
€27.47 Million ≈ $32.12 Million |
-- |
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more